0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
ARTICLE |

CHLOROQUINE DIPHOSPHATE IN TREATMENT OF DISCOID LUPUS ERYTHEMATOSUS

Leon Goldman, M.D.; Donald P. Cole, M.D.; Robert H. Preston, M.D.
JAMA. 1953;152(15):1428-1429. doi:10.1001/jama.1953.63690150002009a.
Text Size: A A A
Published online

Since the initial success of the treatment of lupus erythematosus with quinacrine (Atabrine) by Prokoptchouk1a and Popoff and Kutinscheff1b and later by Page,2 in Europe, attempts have been made to find other less toxic antimalarial agents. Numerous investigators3 in this country also have had good results with the use of quinacrine in this disorder, but they have warned about its toxic effects, which may include production of fatal aplastic anemia.3b

After conferences with Dr. Leon Schmidt,4 director of malarial research at the Institute of Medical Research, Christ Hospital, chloroquine was selected as investigative material, because it is distinctly less toxic, it may be found in the skin in appreciable amounts after oral ingestion, and it does not discolor the skin as does quinacrine. A review of the literature and our own experience revealed that the toxic effects of chloroquine diphosphate are insignificant. Toxic symptoms

Topics

Sign in

Create a free personal account to sign up for alerts, share articles, and more.

Purchase Options

• Buy this article
• Subscribe to the journal

First Page Preview

View Large
First page PDF preview

Figures

Tables

References

Letters

CME
Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.

Multimedia

Some tools below are only available to our subscribers or users with an online account.

Sign in

Create a free personal account to sign up for alerts, share articles, and more.

Purchase Options

• Buy this article
• Subscribe to the journal

Related Content

Customize your page view by dragging & repositioning the boxes below.

Jobs
brightcove.createExperiences();